145 related articles for article (PubMed ID: 36935290)
1. Nutrition Guidance for Patients on Androgen Deprivation Therapy.
Kenfield SA; Van Blarigan EL; Graff RE; Borno HT; Macaire G; Chan JM
Eur Urol Focus; 2023 May; 9(3):427-430. PubMed ID: 36935290
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer.
Sentana-Lledo D; Morgans AK
Curr Oncol Rep; 2024 Mar; 26(3):299-306. PubMed ID: 38376624
[TBL] [Abstract][Full Text] [Related]
3. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
4. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
[TBL] [Abstract][Full Text] [Related]
5. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A;
Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296
[TBL] [Abstract][Full Text] [Related]
6. Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.
Forster RB; Engeland A; Kvåle R; Hjellvik V; Bjørge T
Int J Cancer; 2022 Oct; 151(7):1109-1119. PubMed ID: 35489025
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy.
Haseen F; Murray LJ; O'Neill RF; O'Sullivan JM; Cantwell MM
Trials; 2010 Aug; 11():86. PubMed ID: 20704726
[TBL] [Abstract][Full Text] [Related]
8. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.
Saylor PJ; Keating NL; Smith MR
J Gen Intern Med; 2009 Nov; 24 Suppl 2(Suppl 2):S389-94. PubMed ID: 19838837
[TBL] [Abstract][Full Text] [Related]
10. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
Butler SS; Mahal BA; Moslehi JJ; Nohria A; Dee EC; Makkar R; Whitbeck A; Wangoe J; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2021 Jul; 127(13):2213-2221. PubMed ID: 33905530
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
[TBL] [Abstract][Full Text] [Related]
12. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Preventive Care and Coordination of Care in Prostate Cancer Survivors: A Multi-Institutional Prospective Study.
Holmes JA; Anderson RF; Hoffman LG; Showalter TN; Kasibhatla M; Collins SP; Papagikos MA; Barbosa BD; Alligood K; Stravers LJ; Mahbooba Z; Wang AZ; Chen RC
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):112-115. PubMed ID: 30099132
[TBL] [Abstract][Full Text] [Related]
14. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
Morgans AK; Smith MR; O'Malley AJ; Keating NL
Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
[TBL] [Abstract][Full Text] [Related]
15. The effect of dietary interventions or patterns on the cardiometabolic health of individuals treated with androgen deprivation therapy for prostate cancer: A systematic review.
Wright HH; Walker MA; Broadbent S; Linton C; Keech JJ; Rune KT; Davis CL; Morris M; Zhang A; Newton RU; Marshall S
Maturitas; 2024 Jun; 184():107940. PubMed ID: 38430616
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
[TBL] [Abstract][Full Text] [Related]
17. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.
Muniyan S; Xi L; Datta K; Das A; Teply BA; Batra SK; Kukreja RC
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188383. PubMed ID: 32535158
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study.
Morgia G; Russo GI; Tubaro A; Bortolus R; Randone D; Gabriele P; Trippa F; Zattoni F; Porena M; Mirone V; Serni S; Del Nero A; Lay G; Ricardi U; Rocco F; Terrone C; Pagliarulo A; Ludovico G; Vespasiani G; Brausi M; Simeone C; Novella G; Carmignani G; Leonardi R; Pinnarò P; De Paula U; Corvò R; Tenaglia R; Siracusano S; Mantini G; Gontero P; Savoca G; Ficarra V;
Urology; 2016 Oct; 96():165-170. PubMed ID: 27402374
[TBL] [Abstract][Full Text] [Related]
20. Nutrition care guidelines for men with prostate cancer undergoing androgen deprivation therapy: do we have enough evidence?
Barnes KA; Ball LE; Galvão DA; Newton RU; Chambers SK
Prostate Cancer Prostatic Dis; 2019 May; 22(2):221-234. PubMed ID: 30279584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
